Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04288427 · ClinicalTrials.gov registry record · NA
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
A NA study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT04288427 is a NA study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 120 participants, below the 548-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04288427, a NA study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.
Conditions Studied
Interventions
- DRUG Finasteride
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04288427
The ClinicalTrials.gov registry entry for NCT04288427 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 548-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (78% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which Finasteride is the first listed.
NCT04288427 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04288427 about?
NCT04288427 is a clinical study titled "5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy". The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified p...
What is the current status of trial NCT04288427?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2020-09-25. Estimated completion is 2026-11-30.
What conditions does trial NCT04288427 study?
This clinical trial studies the following conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Prostate Disease, Prostate Hyperplasia, Urinary Obstruction.
What interventions are being tested in trial NCT04288427?
The interventions under investigation include: Finasteride (DRUG).
Who is sponsoring clinical trial NCT04288427?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04288427 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ambulatory Long Length URodynamics Evaluation
RECRUITING · NA
-
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
RECRUITING · NA
-
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
RECRUITING · NA
-
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
RECRUITING · NA
-
PRescription Exercise for Older Men With Urinary Disease
RECRUITING · NA
-
Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of Prostate
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Benign Prostatic Hyperplasia
All registered trials for this condition
Lower Urinary Tract Symptoms
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.